After completing this course, the reader should be able to:1. Describe the current epidemiologic trends in hepatoblastoma.2. Identify the genetic syndromes that are seen in a subset of liver tumors.3. Assess the need for complete tumor resection in the treatment of liver tumors in children as well as the increasingly important option of liver transplantation for those patients with unresectable tumors.4. Discuss the impact of the hepatitis vaccine in reducing the incidence of hepatocellular carcinoma.5. Explain the prognostic impact of different histologic subtypes of hepatoblastoma.6. Promote the need for future clinical trials in testing new agents for hepatocellular carcinoma in children.7. Employ the different staging systems used in liver tumors, including the traditional North American postsurgical staging system and the European presurgical staging system using imaging.This article is available for continuing medical education credit at CME.TheOncologist.com. CME CME ABSTRACT

Given the knowledge gap under which biosimilars are developed, data to establish biosimilarity should go beyond a simple comparability exercise.

No abstract

The availability of biosimilars as lower-cost biologics must carefully consider issues of safety, efficacy and traceability. Stringent pharmacovigilance procedures are required to detect potential differences in safety signals between biosimilars and their reference products. Pharmacovigilance of biologics should include processes that are easily used by prescribing practitioners to ensure that data are consistent and new safety signals are properly reported and assigned to the correct product.